Literature DB >> 17913540

Extended immunization intervals enhance the immunogenicity and protective efficacy of plasmid DNA vaccines.

Gary T Brice1, Carlota Dobaño, Martha Sedegah, Maureen Stefaniak, Norma L Graber, Joseph J Campo, Daniel J Carucci, Denise L Doolan.   

Abstract

Effective vaccines against infectious diseases and biological warfare agents remain an urgent public health priority. Studies have characterized the differentiation of effector and memory T cells and identified a subset of T cells capable of conferring enhanced protective immunity against pathogen challenge. We hypothesized that the kinetics of T cell differentiation influences the immunogenicity and protective efficacy of plasmid DNA vaccines, and tested this hypothesis in the Plasmodium yoelii murine model of malaria. We found that increasing the interval between immunizations significantly enhanced the frequency and magnitude of CD8+ and CD4+ T cell responses as well as protective immunity against sporozoite challenge. Moreover, the interval between immunizations was more important than the total number of immunizations. Immunization interval had a significantly greater impact on T cell responses and protective immunity than on antibody responses. With prolonged immunization intervals, T cell responses induced by homologous DNA only regimens achieved levels similar to those induced by heterologous DNA prime/ virus boost immunization at standard intervals. Our studies establish that the dosing interval significantly impacts the immunogenicity and protective efficacy of plasmid DNA vaccines.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17913540     DOI: 10.1016/j.micinf.2007.07.009

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


  17 in total

1.  Tunable degradation of acetalated dextran microparticles enables controlled vaccine adjuvant and antigen delivery to modulate adaptive immune responses.

Authors:  Naihan Chen; Monica M Johnson; Michael A Collier; Matthew D Gallovic; Eric M Bachelder; Kristy M Ainslie
Journal:  J Control Release       Date:  2018-02-02       Impact factor: 9.776

2.  Safety and Immunological Efficacy of a DNA Vaccine Encoding the Androgen Receptor Ligand-Binding Domain (AR-LBD).

Authors:  Brian M Olson; Eric S Bradley; Thomas Sawicki; Weixiong Zhong; Erik A Ranheim; Jordan E Bloom; Viswa T Colluru; Laura E Johnson; Brian T Rekoske; Jens C Eickhoff; Douglas G McNeel
Journal:  Prostate       Date:  2017-02-09       Impact factor: 4.104

3.  Investigation of tunable acetalated dextran microparticle platform to optimize M2e-based influenza vaccine efficacy.

Authors:  Naihan Chen; Matthew D Gallovic; Pamela Tiet; Jenny P-Y Ting; Kristy M Ainslie; Eric M Bachelder
Journal:  J Control Release       Date:  2018-09-24       Impact factor: 9.776

4.  Malaria DNA vaccine gp96NTD-CSP elicits both CSP-specific antibody and CD8(+) T cell response.

Authors:  Zhangping Tan; TaoLi Zhou; Hong Zheng; Yan Ding; Wenyue Xu
Journal:  Parasitol Res       Date:  2015-03-20       Impact factor: 2.289

5.  Highly persistent and effective prime/boost regimens against tuberculosis that use a multivalent modified vaccine virus Ankara-based tuberculosis vaccine with interleukin-15 as a molecular adjuvant.

Authors:  Kristopher Kolibab; Amy Yang; Steven C Derrick; Thomas A Waldmann; Liyanage P Perera; Sheldon L Morris
Journal:  Clin Vaccine Immunol       Date:  2010-03-31

Review 6.  Immune mechanisms in malaria: new insights in vaccine development.

Authors:  Eleanor M Riley; V Ann Stewart
Journal:  Nat Med       Date:  2013-02       Impact factor: 53.440

7.  Sterile protection against Plasmodium knowlesi in rhesus monkeys from a malaria vaccine: comparison of heterologous prime boost strategies.

Authors:  George Jiang; Meng Shi; Solomon Conteh; Nancy Richie; Glenna Banania; Harini Geneshan; Anais Valencia; Priti Singh; Joao Aguiar; Keith Limbach; Kurt I Kamrud; Jonathan Rayner; Jonathan Smith; Joseph T Bruder; C Richter King; Takafumi Tsuboi; Satoru Takeo; Yaeta Endo; Denise L Doolan; Thomas L Richie; Walter R Weiss
Journal:  PLoS One       Date:  2009-08-10       Impact factor: 3.240

8.  Preclinical evaluation of the immunogenicity and safety of plasmid DNA-based prophylactic vaccines for human cytomegalovirus.

Authors:  Jukka Hartikka; Vesselina Bozoukova; Jane Morrow; Denis Rusalov; Mark Shlapobersky; Qun Wei; Sou Boutsaboualoy; Ming Ye; Mary K Wloch; John Doukas; Sean Sullivan; Alain Rolland; Larry R Smith
Journal:  Hum Vaccin Immunother       Date:  2012-08-24       Impact factor: 3.452

Review 9.  Prime-boost approaches to tuberculosis vaccine development.

Authors:  Neha Dalmia; Alistair J Ramsay
Journal:  Expert Rev Vaccines       Date:  2012-10       Impact factor: 5.217

10.  A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel with CPG 7909, using two different formulations and dosing intervals.

Authors:  Ruth D Ellis; Gregory E D Mullen; Mark Pierce; Laura B Martin; Kazutoyo Miura; Michael P Fay; Carole A Long; Donna Shaffer; Allan Saul; Louis H Miller; Anna P Durbin
Journal:  Vaccine       Date:  2009-05-15       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.